Abstract
The INK4a/ARF locus encodes two unrelated cell cycle-regulatory proteins that both function in tumor suppression, p16INK4a and p14ARF. In human tumors including breast cancer, alterations affecting selectively p14ARF have been poorly analysed. We have performed a comprehensive analysis of the inactivation mechanisms (mutation, homozygous and hemizygous deletion, and promoter hypermethylation) in a large series of 100 primary breast carcinomas. RT–PCR showed expression variable of the p14ARF transcript, with 17% demonstrating overexpression and 26% demonstrating decreased expression. No detectable alterations were observed in the majority of cases with overexpressed p14ARF mRNA, but 77% of tumors with decreased expression presented at least one of these genetic/epigenetic alterations. Nevertheless, a statistically significant correlation was observed between decreased p14ARF expression and several poor prognostic parameters.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM . 1996 Clin. Cancer Res. 2: 1993–1998
Chin L, Pomerantz J, DePinho RA . 1998 Trends Biochem. Sci. 23: 291–296
Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG . 2000 Cancer Res. 60: 129–133
Fitzgerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA . 1996 Proc. Natl. Acad. Sci. USA 93: 8541–8545
Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E . 1998 Cancer Res. 58: 3926–3931
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826
Herranz M, Urioste M, Santos J, Rivas C, Martinez B, Benitez J, Fernandez-Piqueras J . 1999 Leukemia 13: 808–810
Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K, Yuasa Y . 2000 Int. J. Cancer 87: 654–658
Iwato M, Tachibana O, Tohma Y, Arakawa Y, Nitta H, Hasegawa M, Yamashita J, Hayashi Y . 2000 Cancer Res. 60: 2113–2115
Kamijo T, Zindy F, Roussel MF, Quelle DQ, Downing JR, Ashmun RA, Grosveld G, Sherr CJ . 1997 Cell 91: 649–659
Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K . 1998 Gene. Chromosome. Canc. 23: 273–277
Liggett WH, Sidransky D . 1998 J. Clin. Oncol. 16: 1197–1206
Markl IDC, Jones PA . 1998 Cancer Res. 58: 5348–5353
Oto M, Miyake S, Yuasa Y . 1993 Ann. Biochem. 213: 19–22
Quelle DE, Zindy F, Ashmun RA, Sherr CJ . 1995 Cell 83: 993–100
Quelle DE, Cheng M, Ashmun RA, Sherr CJ . 1997 Proc. Natl. Acad. Sci. USA 94: 669–673
Robertson KD, Jones PA . 1998 Mol. Cell. Biol. 18: 6457–6473
Sanchez-Céspedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, Yang SC, Jen J, Sidransky D . 1999 Oncogene 18: 5843–5849
Serrano M, Hannon GJ, Beach D . 1993 Nature 366: 704–707
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A . 1995 Cancer Res. 55: 2988–2994
Takemoto S, Trovato R, Cereseto A, Nicot C, Kislyakova T, Casareto L, Waldmann T, Torelli G, Franchini G . 2000 Blood 95: 3939–3944
Tao W, Levine AJ . 1999 Proc. Natl. Acad. Sci. USA 96: 6937–6941
Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC . 1998 Oncogene 17: 2779–2785
Zhang Y, Xiong Y, Yarbrough WG . 1998 Cell 92: 725–734
Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A, Trias M, Wiencke JK . 2000 Carcinogenesis 21: 2057–2064
Zindy F, Eischen CM, Randle D, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF . 1998 Genes Dev. 12: 2424–2434
Acknowledgements
We are grateful to Mr Robin Rycroft for his assistance with the English language, revision and preparation of the manuscript. This work was supported by grants from the Fundación Banco Santander Central Hispano, Aventis Pharma S.A and CAM 08.1/0069/20002.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Silva, J., Domínguez, G., Silva, J. et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene 20, 4586–4590 (2001). https://doi.org/10.1038/sj.onc.1204617
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204617
Keywords
This article is cited by
-
Oncogene-induced senescence mediated by c-Myc requires USP10 dependent deubiquitination and stabilization of p14ARF
Cell Death & Differentiation (2018)
-
Biological significance of promoter hypermethylation of p14/ARF gene: Relationships to p53 mutational status in Tunisian population with colorectal carcinoma
Tumor Biology (2014)
-
BCL6 overexpression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma
Tumor Biology (2014)
-
NUMB controls p53 tumour suppressor activity
Nature (2008)
-
p14ARF expression in invasive breast cancers and ductal carcinoma in situ– relationships to p53 and Hdm2
Breast Cancer Research (2004)